查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046223

植物來源生物製造市場－全球產業規模、佔有率、趨勢、機會和預測：按產品類型、技術、原料、最終用戶、地區和競爭格局分類，2021-2031年

Plant Based Biomanufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type By Technology By Source By End User By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球植物來源生物製造市場預計將大幅擴張，從 2025 年的 68.1 億美元成長到 2031 年的 87.2 億美元，複合年成長率為 4.21%。

這個創新領域利用植物系統（例如整株作物和植物細胞培養）來生產高價值的生物來源產品，例如治療性蛋白質、工業酵素和替代食品配料。推動市場成長的主要因素是與傳統的哺乳動物細胞培養相比，上游工程具有顯著的成本優勢，以及利用現有農業基礎設施實現的快速規模化生產。此外，植物宿主固有的安全性，消除了動物源系統中常見的人類病原體污染風險，也是一項關鍵的業務促進因素。最具變革性的因素無疑是成本效益高的生產方式和較低的資本投入。與需要昂貴生物反應器的傳統系統不同，基於植物的方法利用農田和溫室，從而大幅降低了上游工程投資和營運成本。例如，BioBetter公司2025年8月發布的白皮書《生長因子的植物分子農業》重點介紹了其煙草植物平台如何實現永續且可擴展的重組蛋白生產，而無需傳統的發酵基礎設施，從而克服了高成本瓶頸。生物製藥和生物相似藥的全球需求不斷成長，也推動了市場擴張，這需要可擴展的替代生產方法。植物來源平台正展現出其商業性可行性。例如，Protalix BioTherapeutics於2025年3月宣布，2024會計年度的年銷售額為5,300萬美元（年成長31%），主要來自其植物細胞表現療法。 PlantForm Corporation與Baiya Phytopharm於2025年合作生產人工植物來源外吐小體，也顯示了其應用範圍的不斷擴大。儘管有這些強勁的促進因素，但下游製程中加工和純化的高複雜性和高成本仍然是市場擴張的主要障礙。這項技術壁壘往往會抵消上游工程製程所實現的成本效益，因為根據嚴格標準分離和純化目標分子需要複雜且資本密集的基礎設施和昂貴的耗材，從而導致最終產品成本增加。這項經濟挑戰導致商業夥伴疏遠，並限制了植物性產品的應用範圍，使其僅限於高利潤的小眾應用領域，而非大眾市場產品。這造成了謹慎的投資環境和資金限制。根據良好食品研究所（Good Food Institute）的報告預測，到2025年，植物來源產品的私人投資預計僅為3.09億美元左右。同時，市場也呈現顯著的趨勢，尤其是植物來源生長因子在細胞農業和培養肉領域的商業化進程急劇加快。這項策略轉變將使生物製藥企業能夠克服細胞培養肉生產中巨大的成本障礙。冰島公司ORF Genetics就是一個典型的例子。根據Silicon Canals在2025年9月報道，該公司籌集了500萬歐元，用於擴大其大麥衍生的MESOkine產品組合，併計劃到2027年將其產能提高14倍。同時，生物製藥公司正在利用植物系統合成用於高階護膚的複雜生物活性化合物，加速進入高價值化妝品原料市場。這股趨勢利用「清潔美容」概念，發展出植物來源的表皮生長因子和膠原蛋白，這些成分具有卓越的穩定性和生物相似性，且不引發倫理問題。根據《全球化妝品產業》2025年1月刊報道，Core Biogenesis的植物來源油體-蛋白融合物比傳統的胜肽類活性成分穩定10倍，這進一步印證了其性能優勢。

市場概覽
預測期 2027-2031
市場規模：2025年 68.1億美元
市場規模：2031年 87.2億美元
複合年成長率：2026-2031年 4.21%
成長最快的細分市場 抗體
最大的市場 北美洲

市場促進因素

在全球植物來源生物製造市場中，最具變革性的因素是成本效益高的生產方式和資本投入的降低。與需要昂貴且維護成本高昂的不銹鋼生物反應器的傳統哺乳動物細胞培養系統不同，植物來源系統利用農田和可控溫室作為天然的生產宿主。這種根本性的轉變顯著降低了上游工程資本投入和營運成本，使得生產用於更廣泛應用的複雜蛋白質在經濟上成為可能。根據BioBetter公司2025年8月發布的報告，其菸草植物平台透過實現重組蛋白的永續和可擴展生產，無需傳統的發酵基礎設施，從而解決了高成本的瓶頸問題。同時，全球對生物製藥和生物相似藥日益成長的需求也推動了這個市場的發展，這些需求需要能夠滿足商業性生產規模要求的替代生產方法。隨著重磅生物製藥專利的到期以及對更容易獲得的療法的需求不斷增加，植物來源平台正在證明商業性大規模供應已通過核准藥物的商業能力。這一市場前景也體現在成熟產業參與者的財務表現中。 2025年3月，Protalix BioTherapeutics公佈其年銷售額為5,300萬美元，較去年同期成長31%，主要得益於其植物細胞表現療法Elfabrio的銷售成長。作為該領域應用範圍不斷擴大的一個例證，PlantForm Corporation於2025年與Baiya Phytopharm達成策略合作，開始生產人工合成的植物來源源外泌體。這進一步拓展了該生物製造技術的應用領域。

市場挑戰

下游加工和純化過程的複雜性和高成本是限制全球植物來源生物製造市場擴張的主要瓶頸。雖然植物系統在上游工程製程中具有可擴展性，但分離和純化目標分子以達到醫藥或食品級標準的技術和經濟負擔往往會抵消培養階段所獲得的成本效益。這一階段需要複雜且資本密集的基礎設施和昂貴的耗材，從而顯著增加最終產品的成本。因此，無法確保與傳統製造方法的價格競爭力，這阻礙了潛在商業夥伴的進入，並將該技術的應用限制在高利潤的利基應用領域，而非面向大眾市場的通用產品。這種經濟壁壘透過提高進入門檻和抑制必要工業產能的發展，直接阻礙了市場成長。純化設施所需的高額資本投資使得投資回報率難以保證，從而創造了謹慎的投資環境，並消耗了該行業必要的擴張資金。據良好食品研究所（Good Food Institute）稱，到2025年，植物來源行業將面臨資金籌措，據報道，私人對植物性產品的投資約為3.09億美元。這種資金短缺源自於擴大複雜加工基礎設施所帶來的財務風險，直接延緩了滿足全球需求所需的供應鏈建設。

市場趨勢

市場正見證著專為細胞農業和培養肉產業量身定做的植物來源生長因子商業化進程的顯著成長。這一趨勢對於利用分子農業平台生產非動物源細胞激素和培養基成分的生物製藥企業而言，標誌著一個策略轉折點。這使他們能夠克服細胞培養肉生產中巨大的成本壁壘，同時開闢人類治療領域之外的盈利的銷售管道。這種向產業規模擴張的趨勢在近期對專用生產能力的投資中可見一斑。 2025年9月，《矽谷運河》（Silicon Canals）報道稱，冰島的ORF Genetics公司已成功資金籌措500萬歐元，用於擴大其大麥衍生MESOkine產品組合。該公司計劃在2027年將產能提高14倍，以滿足培養肉產業日益成長的需求。同時，生物製藥公司正利用植物系統合成用於高階護膚市場的複雜生物活性化合物，加速進入高價值化妝品原料領域。隨著消費者偏好轉向“清潔美容”，各公司正利用這一趨勢開發植物來源的表皮生長因子和膠原蛋白。與哺乳動物來源的同類產品相比，這些產品具有更優異的穩定性和生物相似性，且避免了動物提取帶來的倫理問題。這種功效優勢正推動配方研發人員迅速採用這些產品。 2025年1月，全球化妝品產業協會證實，Core Biogenesis公司的植物來源油體-蛋白融合物比傳統的胜肽類活性成分穩定10倍，這充分證明了植物來源成分在高級皮膚病學應用中的卓越性能。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：植物植物來源生物製造的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（抗體、疫苗、蛋白質、生物製藥、酵素、其他）
    • 依技術（上游工程與下游製程）分類
    • 依原料（整株植物、植物細胞、種子、葉子等）
    • 按最終用戶（生物技術和製藥公司、契約製造組織等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美植物性植物來源製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲植物來源生物製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區植物來源生物製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲植物植物來源生物製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲植物植物來源生物製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球植物來源生物製造市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Amyris, Inc.
  • Ginkgo Bioworks, Inc.
  • Zymergen Inc.
  • Evolva Holding SA
  • Tate & Lyle PLC
  • Molecular Assemblies, Inc.
  • Cambia Biologics
  • Green Biologics Ltd.
  • Novozymes A/S
  • Kiverdi, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7734

The Global Plant-Based Biomanufacturing Market is set for considerable expansion, with projections indicating growth from USD 6.81 Billion in 2025 to USD 8.72 Billion by 2031, at a 4.21% Compound Annual Growth Rate. This innovative field utilizes plant systems, such as whole crops and plant cell cultures, to create high-value biological products like therapeutic proteins, industrial enzymes, and alternative food ingredients. A primary catalyst for this market's growth is the significant cost advantage in upstream production compared to traditional mammalian cell cultures, alongside the rapid scalability offered by leveraging existing agricultural infrastructure. Furthermore, the inherent safety of plant hosts, which eliminates the risk of human pathogen contamination found in animal-derived systems, serves as a crucial operational driver. The most transformative factor is indeed cost-effective production and reduced capital expenditure; unlike traditional systems requiring expensive bioreactors, plant-based methods utilize agricultural fields or greenhouses, dramatically lowering upstream investment and operational costs. For instance, BioBetter's August 2025 'Plant Molecular Farming of Growth Factors' white paper highlights their tobacco plant platform's ability to address high-cost bottlenecks by enabling sustainable, scalable recombinant protein production without conventional fermentation infrastructure. This market expansion is also driven by the escalating global demand for biologics and biosimilars, necessitating scalable alternative production methods. Plant-based platforms are demonstrating their commercial viability, as seen in Protalix BioTherapeutics' March 2025 report of $53.0 million in annual revenue for Fiscal Year 2024, a 31% increase largely due to its plant-cell-expressed therapeutic, Elfabrio, and PlantForm Corporation's 2025 collaboration with Baiya Phytopharm to produce artificial plant-made exosomes, showcasing broadening applications.Despite these strong drivers, a significant impediment to market expansion is the extensive complexity and high expenditure associated with downstream processing and purification. This technical hurdle often negates the cost efficiencies achieved during upstream cultivation, as isolating and purifying target molecules to stringent standards requires sophisticated, capital-intensive infrastructure and expensive consumables, thereby increasing the final cost of goods. This economic challenge consequently deters commercial partners and limits adoption to high-margin niche applications rather than mass-market commodities, contributing to a cautious investment climate and constraining capital, with private investment in plant-based products reported at approximately $309 million in 2025 by the Good Food Institute. Concurrently, the market is experiencing notable trends, including a distinct surge in the commercialization of plant-made growth factors specifically for the cellular agriculture and cultivated meat sectors. This strategic pivot allows biomanufacturers to address critical cost barriers in cell-based meat production, exemplified by Iceland's ORF Genetics securing €5 million to expand its barley-based MESOkine portfolio with plans for a fourteenfold production capacity increase by 2027, as reported by Silicon Canals in September 2025. Simultaneously, biomanufacturers are increasingly expanding into the high-value cosmetic ingredients sector, leveraging plant systems to synthesize complex bioactive compounds for premium skincare. This trend capitalizes on the "clean beauty" movement, developing plant-derived epidermal growth factors and collagen that offer superior stability and bio-similarity without ethical concerns, a performance advantage confirmed by Core Biogenesis' plant-derived oleosome-protein fusions being 10 times more stable than conventional peptide-based actives, according to Global Cosmetic Industry in January 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.81 Billion
Market Size 2031USD 8.72 Billion
CAGR 2026-20314.21%
Fastest Growing SegmentAntibodies
Largest MarketNorth America

Market Driver

The most transformative driver for the Global Plant-Based Biomanufacturing Market is cost-effective production and reduced capital expenditure. Unlike traditional mammalian cell culture systems that necessitate expensive, high-maintenance stainless steel bioreactors, plant-based systems utilize agricultural fields or controlled greenhouses as natural production hosts. This fundamental shift significantly lowers upstream capital investment and operational costs, making the manufacturing of complex proteins economically viable for a broader range of applications. According to BioBetter in August 2025, their tobacco plant platform addresses critical high-cost bottlenecks by enabling sustainable, scalable production of recombinant proteins without the need for conventional fermentation infrastructure. Simultaneously, the market is propelled by the rising global demand for biologics and biosimilars, which necessitates alternative production modalities capable of meeting commercial volume requirements. As patents for blockbuster biologics expire and the need for accessible therapeutics grows, plant-based platforms are proving their commercial capability to deliver approved drugs at scale. This market validation is evident in the financial performance of established sector players; Protalix BioTherapeutics reported annual revenue of $53.0 million in March 2025, a 31% increase driven primarily by sales of its plant-cell-expressed therapeutic, Elfabrio. Highlighting the sector's expanding versatility, PlantForm Corporation initiated a strategic collaboration with Baiya Phytopharm in 2025 to produce artificial plant-made exosomes, further diversifying the applications of this biomanufacturing approach.

Market Challenge

The extensive complexity and high expenditure associated with downstream processing and purification constitute a significant bottleneck restricting the expansion of the Global Plant-Based Biomanufacturing Market. While plant systems offer upstream scalability, the technoeconomic burden of isolating and purifying target molecules to pharmaceutical or food-grade standards often negates the cost efficiencies gained during cultivation. This stage necessitates sophisticated, capital-intensive infrastructure and expensive consumables, which drastically increases the final cost of goods. Consequently, the inability to achieve price parity with traditional manufacturing methods deters potential commercial partners and limits the technology's adoption to high-margin niche applications rather than mass-market commodities. This economic hurdle directly hampers market growth by creating a high barrier to entry and stalling the development of necessary industrial capacity. The substantial capital expenditure required for purification facilities makes securing return on investment difficult, leading to a cautious investment climate that starves the sector of essential expansion funds. According to the Good Food Institute, the industry faced a constrained capital environment in 2025, with private investment in plant-based products reported at approximately $309 million. This restricted funding, driven by the financial risks of scaling complex processing infrastructure, directly slows the construction of the supply chains needed to meet global demand.

Market Trends

The market is witnessing a distinct surge in the commercialization of plant-made growth factors tailored specifically for the cellular agriculture and cultivated meat sectors. This trend represents a strategic pivot for biomanufacturers who are leveraging their molecular farming platforms to produce animal-free cytokines and growth media components, thereby addressing the critical cost barriers of cell-based meat production while opening a lucrative revenue channel beyond human therapeutics. This industrial scaling is exemplified by recent investments in dedicated manufacturing capacity; Silicon Canals reported in September 2025 that Iceland's ORF Genetics secured €5 million to expand its barley-based MESOkine portfolio, with plans to increase its production capacity fourteenfold by 2027 to support the growing demand from the cultivated meat industry. Simultaneously, biomanufacturers are increasingly expanding into the high-value cosmetic ingredients sector, utilizing plant systems to synthesize complex bioactive compounds for the premium skincare market. By capitalizing on the consumer shift toward "clean beauty," companies are developing plant-derived epidermal growth factors and collagen that offer superior stability and bio-similarity to mammalian equivalents without the ethical concerns of animal extraction. This efficacy advantage is driving rapid adoption among formulation developers, as Global Cosmetic Industry confirmed in January 2025 that Core Biogenesis' plant-derived oleosome-protein fusions are 10 times more stable than conventional peptide-based actives, validating the superior performance of plant-made ingredients for advanced dermatological applications.

Key Market Players

  • Amyris, Inc.
  • Ginkgo Bioworks, Inc.
  • Zymergen Inc.
  • Evolva Holding SA
  • Tate & Lyle PLC
  • Molecular Assemblies, Inc.
  • Cambia Biologics
  • Green Biologics Ltd.
  • Novozymes A/S
  • Kiverdi, Inc.

Report Scope

In this report, the Global Plant Based Biomanufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plant Based Biomanufacturing Market, By Product Type

  • Antibodies
  • Vaccines
  • Proteins
  • Biologics
  • Enzyme
  • Others

Plant Based Biomanufacturing Market, By Technology

  • Upstream
  • Downstream

Plant Based Biomanufacturing Market, By Source

  • Whole Plant
  • Plant Cells
  • Seed
  • Leaf
  • Others

Plant Based Biomanufacturing Market, By End User

  • Biotechnology & Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

Plant Based Biomanufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plant Based Biomanufacturing Market.

Available Customizations:

Global Plant Based Biomanufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plant Based Biomanufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Antibodies, Vaccines, Proteins, Biologics, Enzyme, Others)
    • 5.2.2. By Technology (Upstream v/s Downstream)
    • 5.2.3. By Source (Whole Plant, Plant Cells, Seed, Leaf, Others)
    • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Plant Based Biomanufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Source
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plant Based Biomanufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Source
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Plant Based Biomanufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Source
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Plant Based Biomanufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Source
        • 6.3.3.2.4. By End User

7. Europe Plant Based Biomanufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Source
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Plant Based Biomanufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Source
        • 7.3.1.2.4. By End User
    • 7.3.2. France Plant Based Biomanufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Source
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Plant Based Biomanufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Source
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Plant Based Biomanufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Source
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Plant Based Biomanufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Source
        • 7.3.5.2.4. By End User

8. Asia Pacific Plant Based Biomanufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Source
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Plant Based Biomanufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Source
        • 8.3.1.2.4. By End User
    • 8.3.2. India Plant Based Biomanufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Source
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Plant Based Biomanufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Source
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Plant Based Biomanufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Source
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Plant Based Biomanufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Source
        • 8.3.5.2.4. By End User

9. Middle East & Africa Plant Based Biomanufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Source
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Plant Based Biomanufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Source
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Plant Based Biomanufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Source
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Plant Based Biomanufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Source
        • 9.3.3.2.4. By End User

10. South America Plant Based Biomanufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Source
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Plant Based Biomanufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Source
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Plant Based Biomanufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Source
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Plant Based Biomanufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Source
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Plant Based Biomanufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amyris, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ginkgo Bioworks, Inc.
  • 15.3. Zymergen Inc.
  • 15.4. Evolva Holding SA
  • 15.5. Tate & Lyle PLC
  • 15.6. Molecular Assemblies, Inc.
  • 15.7. Cambia Biologics
  • 15.8. Green Biologics Ltd.
  • 15.9. Novozymes A/S
  • 15.10. Kiverdi, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer